Literature DB >> 7043707

Introduction to vancomycin.

R S Griffith.   

Abstract

The emergence of antibiotic-resistant strains of Staphylococcus aureus in hospitalized patients during the early 1950s stimulated research designed to develop new antimicrobial agents that would combat the "golden plague." Vancomycin, produced by a microorganism found in a soil sample from the jungle trails of Borneo, was shown to have antistaphylococcal activity and to be relatively safe when administered to patients with staphylococcal infections. In a recent resurgence in the use of vancomycin, investigators have reported the value of this antibiotic in the treatment of staphlococcal infections against which the newer antistaphylococcal antibiotics are ineffective. In addition, vancomycin is being used for prophylaxis in patients undergoing renal dialysis, for treatment of antibiotic-induced enterocolitis, and in combination with an aminoglycoside for "sterilization" of the intestinal tract of patients with cancer.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7043707

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  19 in total

Review 1.  Risk of hepatic events in patients treated with vancomycin in clinical studies: a systematic review and meta-analysis.

Authors:  Yan Chen; Xiao Yan Yang; Michael Zeckel; Chris Killian; Kenneth Hornbuckle; Arie Regev; Simon Voss
Journal:  Drug Saf       Date:  2011-01-01       Impact factor: 5.606

Review 2.  Vancomycin- and erythromycin-induced hearing loss in humans.

Authors:  R E Brummett; K E Fox
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

3.  Vancomycin-Associated Cast Nephropathy.

Authors:  Yosu Luque; Kevin Louis; Chantal Jouanneau; Sandrine Placier; Emmanuel Esteve; Dominique Bazin; Eric Rondeau; Emmanuel Letavernier; Alice Wolfromm; Clément Gosset; Anna Boueilh; Maren Burbach; Perrine Frère; Marie-Christine Verpont; Sophie Vandermeersch; Dominique Langui; Michel Daudon; Vincent Frochot; Laurent Mesnard
Journal:  J Am Soc Nephrol       Date:  2017-01-12       Impact factor: 10.121

4.  Nitric oxide nanoparticles: pre-clinical utility as a therapeutic for intramuscular abscesses.

Authors:  David Schairer; Luis R Martinez; Karin Blecher; Jason Chouake; Parimala Nacharaju; Philip Gialanella; Joel M Friedman; Joshua D Nosanchuk; Adam Friedman
Journal:  Virulence       Date:  2012-01-01       Impact factor: 5.882

5.  Mycobacterium avium-M. intracellulare and Acquired Immunodeficiency Syndrome.

Authors:  E Wolinsky; C R Horsburgh; D L Cohn; R B Roberts; H Masur; R Miller; A Y Tsang; M D Iseman
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

Review 6.  A brief history of antibiotics and select advances in their synthesis.

Authors:  Kyriacos C Nicolaou; Stephan Rigol
Journal:  J Antibiot (Tokyo)       Date:  2017-07-05       Impact factor: 2.649

7.  Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator.

Authors:  Omar Vesga; Maria Agudelo; Beatriz E Salazar; Carlos A Rodriguez; Andres F Zuluaga
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

8.  Risk factors for acute kidney injury in adult patients receiving vancomycin.

Authors:  Diane Cappelletty; Alyse Jablonski; Rose Jung
Journal:  Clin Drug Investig       Date:  2014-03       Impact factor: 2.859

Review 9.  Clinical pharmacokinetics of vancomycin.

Authors:  G R Matzke; G G Zhanel; D R Guay
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

10.  The first vancomycin-intermediate Staphylococcus aureus strains isolated from patients in Thailand.

Authors:  Aroonlug Lulitanond; Chulapan Engchanil; Prajuab Chaimanee; Malai Vorachit; Teruyo Ito; Keiichi Hiramatsu
Journal:  J Clin Microbiol       Date:  2009-04-29       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.